ID: MRFR/Pharma/4393-HCR | February 2021 | Region: Global | 100 pages
Brugada Syndrome Market Overview
Brugada syndrome is a genetic condition resulting in an abnormal electrical activity within the heart, which in turn increases the risk of sudden cardiac death. In some cases, the abnormal heart rhythm often occurs when a patient is at rest and may be triggered by a fever. However, signs and symptoms of Brugada syndrome include fainting, irregular heartbeats or palpitations, and extremely fast and chaotic heartbeat. The signs and symptoms of Brugada syndrome are similar to some other heart rhythm related problems.
The Brugada syndrome market is mainly driven by the high prevalence of heart diseases such as Brugada syndrome and others and a huge demand for diagnosis and treatment methods. Additionally, the increasing availability of diagnostic services for respiratory illness also fuels the growth of the brugada syndrome market. Moreover, favorable reimbursement policies are likely to boost the brugada syndrome market growth.
Many private and government insurance organizations are present in developed countries. Over 50 private insurance companies are present in the U.S. The policies cover more than 75% of the cost of the devices and treatment. For instance, under the Medicare plan in the U.S., if the average cost of single chamber devices is approximately USD 10,000, then USD 7,500 is reimbursed. Additionally, in developed countries such as the UK, Canada, Germany, and others, similar reimbursement policies are available.
The Brugada syndrome market is expected to grow at a CAGR of 6.4% during the forecast period.
FIGURE 1: Global Brugada Syndrome Market, by Region, 2016 (%)
Source: Centers for Disease Control and Prevention, World Health Organization, population reference bureau, Statistics Canada, StatsCan, Centers for Medicare & Medicaid Services, U.S. Census Bureau, Organization for Economic Co-operation and Development, Expert Interview, Market Research Future Analysis, Annual report, White paper, Company Presentation
Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation
The brugada syndrome market is segmented on the basis of diagnosis, treatment, and end-user.
On the basis of diagnosis, the brugada syndrome market is segmented into electrocardiogram, Electrophysiology (EP) test, genetic testing, and others.
On the basis of treatment, the brugada syndrome market is segmented into implantable cardioverter-defibrillator and drug therapy. Drug therapy is further segmented into antiarrhythmic drugs, psychotropic drugs, anesthetics/analgesics, and others. Antiarrhythmic drugs are further sub-segmented into ajmaline, allapinin, ethacizin, flecainide, pilsicainide, procainamide, propafenone, and others. Psychotropic drugs are further sub-segmented into amitriptyline, clomipramine, desipramine, lithium, loxapine, nortriptyline, trifluoperazine, and others. Anesthetics/analgesics are further segmented into bupivacaine, procaine, propofol, and others.
On the basis of end-user, the brugada syndrome market is segmented into hospitals and clinics, surgical centers, diagnostic centers, and others.
Regional Analysis of the Brugada Syndrome Market
The American Brugada syndrome market is segmented into two regions, namely, North America and South America. North America, being the largest market, is mainly driven by the increasing use of electrocardiogram, Electrophysiology (EP) test for the diagnosis of the disease, and huge population base diagnosed with heart-related diseases. Furthermore, the U.S. is the largest market in North America owing to the presence of a large number of market players manufacturing medications for Brugada syndrome and increasing awareness about risk factors and cases of the disease. Canada is expected to be the fastest growing market which is driven by the overall increasing demand for diagnostic medical devices with progress in the medical device sector. South America is expected to be the fastest growing market due to technologically advanced devices for diagnosis and the increasing demand for treatment options of respiratory diseases
The European Brugada syndrome market exhibits a positive growth with an increasing emphasis on the diagnosis of heart diseases such as Brugada syndrome and others. Moreover, Germany and the UK are the major contributors to the growth of the brugada syndrome market. Additionally, the increasing expenditure in healthcare by major countries in Europe also accelerates the growth of the brugada syndrome market.
Asia Pacific is expected to be the fastest growing market whose growth is attributed to a huge demand for diagnostic tests and increasing focus on early diagnosis and treatment of heart diseases. Furthermore, other factors contributing to the growth of the market are lifestyle changes, the influence of western culture among the adults, and addiction to smoking. Additionally, the increasing environmental pollution and exposure to harmful chemicals also attribute to the growth of the brugada syndrome market.
The Middle Eastern and African market for Brugada syndrome exhibits a steady rise with an increase in the number of healthcare facilities providing treatment for chronic conditions and the flourishing growth of the medical device sector especially diagnostic devices such as MRI and CT. In the African region, the awareness about COPD is increasing, thus fueling the growth of the brugada syndrome market.
Key Players in the Brugada Syndrome Market
Some of the key players in brugada syndrome market are GeneDx (U.S), PGxHealth LLC (U.S), Abbott (U.S), GE Healthcare (U.K), Medtronic (U.S.), Pfizer, Inc (U.S), Boston Scientific Corporation (U.S.), GlaxoSmithKline (U.K), Eli Lilly Company (U.S), Taj Pharmaceuticals Ltd (India), and others.
|Market Size||2027: Significant Value|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Diagnosis, Treatment, and End-user|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||GeneDx (U.S), PGxHealth LLC (U.S), Abbott (U.S), GE Healthcare (U.K), Medtronic (U.S.), Pfizer, Inc (U.S), Boston Scientific Corporation (U.S.), GlaxoSmithKline (U.K), Eli Lilly Company (U.S), Taj Pharmaceuticals Ltd (India), and others|
|Key Market Opportunities||Increasing availability of diagnostic services for respiratory illness|
|Key Market Drivers||